Olanzapine is not risk-free during pregnancy, but the available evidence suggests it does not significantly increase the chance of major birth defects. The FDA’s current labeling states that published studies “have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.” That said, olanzapine does carry meaningful metabolic risks for the mother and can cause temporary symptoms in newborns, so the decision to continue or stop it involves weighing those risks against the very real dangers of untreated psychiatric illness.
Birth Defect Risk Compared to Baseline
The background rate of major birth defects in unexposed pregnancies is about 2.7%. A large study across Nordic countries and the United States found a rate of 4.3% among infants exposed to atypical antipsychotics (the class olanzapine belongs to) during early pregnancy. That’s a modest increase in absolute terms, and researchers have noted that separating the effects of medication from the effects of the underlying condition is difficult. Women taking antipsychotics often have other health factors that can independently raise the risk of complications.
The FDA labeling for olanzapine specifically notes that animal studies at doses far exceeding typical human use did not produce birth defects, though some fetal toxicity was observed at those high doses. Taken together, the evidence points to a small potential increase in malformation risk rather than a dramatic one.
Gestational Diabetes and Weight Gain
This is where olanzapine stands out from other antipsychotics. Olanzapine is classified in the highest risk group for weight gain among commonly used antipsychotic medications, and that translates directly into a higher chance of developing gestational diabetes. In one study published in the American Journal of Psychiatry, 12% of women who continued olanzapine in early pregnancy developed gestational diabetes, compared to 4.7% of women who discontinued it. After adjusting for other factors, women who stayed on olanzapine had about 1.6 times the risk.
Gestational diabetes increases the chance of a larger baby, difficult delivery, and blood sugar problems in the newborn. If you’re taking olanzapine and become pregnant, your provider will likely monitor your blood sugar more closely than usual. Some clinicians consider switching to an antipsychotic with a lower metabolic profile when the psychiatric condition allows it, though that decision is highly individual.
Effects on Newborns After Delivery
Babies exposed to olanzapine in the third trimester can experience temporary symptoms after birth, sometimes called neonatal adaptation syndrome. These include stiff or floppy muscle tone, drowsiness, agitation, tremors, breathing difficulties, and trouble feeding. Not all exposed babies develop these symptoms, and most who do recover within hours to days without specific treatment. In some cases, though, prolonged hospital monitoring is needed.
The FDA requires labeling on all antipsychotics warning about these neonatal effects. The symptoms are generally self-limiting, but hospitals will typically observe newborns with known antipsychotic exposure more closely in the first days of life.
What Happens When You Stop
The risks of olanzapine have to be weighed against the risks of going without treatment, and those risks are substantial. Among women with bipolar disorder who discontinued mood-stabilizing medication during pregnancy, 71% experienced at least one recurrence of illness. Women who stopped their medication relapsed twice as often as those who continued, and they reached their first episode more than four times faster.
Most of these relapses were depressive or mixed episodes, and nearly half occurred in the first trimester. Abrupt discontinuation was particularly dangerous, with recurrence happening 11 times faster than with gradual tapering. Untreated psychiatric episodes during pregnancy carry their own serious consequences: poor prenatal care, substance use, malnutrition, self-harm, and preterm delivery are all more common in women experiencing severe, unmanaged illness.
This is the core tension of the decision. Olanzapine poses real but generally modest risks. Stopping it, especially abruptly, can trigger a psychiatric crisis during a vulnerable time.
How Olanzapine Levels Change During Pregnancy
Your body processes drugs differently during pregnancy, and olanzapine is affected by two competing changes. One liver enzyme that breaks down olanzapine becomes less active as pregnancy progresses, which would normally lead to higher drug levels. But another enzyme becomes more active, partially offsetting that effect. Research suggests that maternal olanzapine levels remain relatively stable between the second and third trimesters, meaning major dose adjustments during pregnancy are not always necessary. Your provider may still check blood levels periodically to ensure you’re getting enough of the drug to stay well without unnecessary excess.
Breastfeeding on Olanzapine
Olanzapine passes into breast milk at low levels. Studies estimate that a breastfed infant receives roughly 1 to 4% of the mother’s weight-adjusted dose, which is considered low. Multiple systematic reviews have concluded that olanzapine is one of the preferred antipsychotics for breastfeeding mothers. In most cases, infant blood levels are undetectable.
That said, about 15.6% of breastfed infants exposed to olanzapine showed some adverse effects in one review, primarily drowsiness, irritability, tremor, and sleep disruption. It’s worth noting that some of these effects may carry over from prenatal exposure rather than being caused by breast milk alone. Long-term follow-up is limited but generally shows normal development in exposed infants, with isolated reports of speech or motor delays and poor weight gain in a small number of cases.
If you breastfeed while taking olanzapine, watch for excessive sleepiness, irritability, poor feeding, or unusual movements in your baby. These signs warrant a call to your pediatrician, but they don’t mean breastfeeding is off the table.
Making the Decision
There is no zero-risk option here. Olanzapine slightly raises the chance of metabolic complications and can cause temporary newborn symptoms, but it has not been clearly linked to a meaningful increase in birth defects. Stopping it, on the other hand, carries a high probability of psychiatric relapse, with consequences that can be severe for both mother and baby.
The strongest approach is usually a collaborative one: working with both a psychiatrist and an obstetrician to evaluate whether olanzapine is still the best medication for your situation, monitoring metabolic markers throughout pregnancy, and planning for neonatal observation at delivery. For many women, continuing olanzapine at the lowest effective dose is the safest overall path. For others, a switch to a lower-risk antipsychotic may be possible. The right answer depends on your diagnosis, your history of relapse, and how well other medications have worked for you in the past.